// App-Quantinova.ai

POS0093 (2021) : HETEROGENEITY IN ADVERSE EVENT ASSESSMENT BETWEEN COUNTRIES PARTICIPATING IN AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS USING JANUS KINASE INHIBITORS (THE JAK-POT STUDY)

Researchers

Presenter

  • K. Lauper

Principal Investigators

  • S. A. Bergstra

  • D. Choquette

  • C. Codreanu

  • D. De Cock

  • L. Dreyer

  • O. Elkayam

  • K. Hyrich

  • F. Iannone

  • N. Inanc

  • E. Kristianslund

  • T. K. Kvien

  • B. Leeb

  • G. Lukina

  • D. Nordstrm

  • K. Pavelka

  • M. Pombo-Suarez

  • Z. Rotar

  • M. J. Santos

  • A. Strangfeld

  • D. Courvoisier

  • A. Finckh

Medical Centers

  • Geneva University Hospitals, Geneva, Switzerland

  • LUMC, Radiology, Leiden, Netherlands

  • CHUM, Institut de Recherche en Rhumatologie, Montréal, Canada

  • University of Medicine, Center of Rheumatic Diseases, Bucharest, Romania

  • Katholieke Universiteit Leuven, Skeletal Biology and Engineering Research Centre, Leuven, Belgium

  • Aalborg University Hospital, Rheumatology, DANBIO Aalborg, Aalborg, Denmark

  • Tel aviv University, pschology, Tel Aviv, Israel

  • The University of Manchester, Centre for Epidemiology Versus Arthritis, M13 9PT, United Kingdom

  • University Hospital of Bari, GISEA, Rheumatology, Bari, Italy

  • Marmara University School of Medicine, Istanbul, Turkey

  • Diakonhjemmet Hospital, Rheumatology Unit, Oslo, Norway

  • University Hospital St. Poelten, Rheumatology, St. Poelten, Austria

  • VA Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia

  • Helsinki University, ROB-FIN, Helsinki, Finland

  • Institute of Rheumatology, Prague, Czech Republic

  • Hospital Clinico Universitario, Santiago De Compostela, Spain

  • University Medical Centre Ljubljana & Universitiy of Ljubljana, Rheumatology, Ljubljana, Slovenia

  • Rheuma.pt, RA, Lisbon, Portugal

  • Faculdade de Medicina de Lisboa, Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal

  • DRFZ, Programme Area Epidemiology, Berlin, Germany

Locations

  • Switzerland

  • Netherlands

  • Canada

  • Romania

  • Belgium

  • Denmark

  • Israel

  • United Kingdom

  • Italy

  • Turkey

  • Norway

  • Austria

  • Russia

  • Finland

  • Czech Republic

  • Spain

  • Slovenia

  • Portugal

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • BMS Infotech

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved